ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · IEX Real-Time Price · USD
0.182
+0.001 (0.55%)
Mar 28, 2024, 1:41 PM EDT - Market open

ReShape Lifesciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202220212020201920182017201620152014
Net Income
-46.21-63.15-21.63-23.68-37.38-34.77-20.47-15.55-9.88
Depreciation & Amortization
2.151.971.670.890.580.330.190.170.17
Share-Based Compensation
2.0912.231.322.984.693.240.560.210.19
Other Operating Activities
20.0733.5710.09-3.072.670.570.353.79-0.38
Operating Cash Flow
-21.9-15.38-8.55-22.87-29.43-30.62-19.37-11.39-9.91
Capital Expenditures
-0.09-0.35-0.39-0.19-1.28-1.04-0.35-0.13-0.27
Acquisitions
02.21-2000000
Change in Investments
0002.5520.8-20.816.552.91-7.65
Investing Cash Flow
-0.091.86-2.392.3619.52-21.866.22.78-7.92
Share Issuance / Repurchase
3.1346.030.6823.389.970.4381.75013.62
Debt Issued / Paid
0-12.7310.4-10-0.030051.96
Other Financing Activities
---00.050.181.040.066.61
Financing Cash Flow
3.1333.311.0813.389.990.6182.795.0622.19
Exchange Rate Effect
00.03-0.1100000.010.01
Net Cash Flow
-18.8619.810.02-7.130.08-51.8769.62-3.554.38
Free Cash Flow
-21.99-15.73-8.94-23.06-30.71-31.67-19.72-11.53-10.18
Free Cash Flow Margin
-195.68%-115.64%-79.12%-702.83%-337.48%-319.42%-581.20%-285.34%-287.51%
Free Cash Flow Per Share
-51.83-71.97-114.48-734.90-2420.04-2841.29-7004.11-30160.68-28719.74
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).